Endothelial Dll4 overexpression reduces vascular response and inhibits tumor growth and metastasization in vivo
Open Access
- 14 March 2017
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-13
Abstract
The inhibition of Delta-like 4 (Dll4)/Notch signaling has been shown to result in excessive, nonfunctional vessel proliferation and significant tumor growth suppression. However, safety concerns emerged with the identification of side effects resulting from chronic Dll4/Notch blockade. Alternatively, we explored the endothelial Dll4 overexpression using different mouse tumor models. We used a transgenic mouse model of endothelial-specific Dll4 overexpression, previously produced. Growth kinetics and vascular histopathology of several types of solid tumors was evaluated, namely Lewis Lung Carcinoma xenografts, chemically-induced skin papillomas and RIP1-Tag2 insulinomas. We found that increased Dll4/Notch signaling reduces tumor growth by reducing vascular endothelial growth factor (VEGF)-induced endothelial proliferation, tumor vessel density and overall tumor blood supply. In addition, Dll4 overexpression consistently improved tumor vascular maturation and functionality, as indicated by increased vessel calibers, enhanced mural cell recruitment and increased network perfusion. Importantly, the tumor vessel normalization is not more effective than restricted vessel proliferation, but was found to prevent metastasis formation and allow for increased delivery to the tumor of concomitant chemotherapy, improving its efficacy. By reducing endothelial sensitivity to VEGF, these results imply that Dll4/Notch stimulation in tumor microenvironment could be beneficial to solid cancer patient treatment by reducing primary tumor size, improving tumor drug delivery and reducing metastization. Endothelial specific Dll4 overexpression thus appears as a promising anti-angiogenic modality that might improve cancer control.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (PTDC/SAU-ONC/116164/2009, PTDC/CVT/115703/2009)
This publication has 44 references indexed in Scilit:
- Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical TrialsGastroenterology Research and Practice, 2014
- Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesisBMC Cancer, 2010
- Targeting DLL4 in Tumors Shows Preclinical Activity But Potentially Significant ToxicityFuture Oncology, 2010
- DLL4 Blockade Inhibits Tumor Growth and Reduces Tumor-Initiating Cell FrequencyCell Stem Cell, 2009
- Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formationNature, 2008
- The Role of the Vascular Endothelial Growth Factor–Delta-like 4 Ligand/Notch4-Ephrin B2 Cascade in Tumor Vessel Remodeling and Endothelial Cell FunctionsCancer Research, 2006
- Up-Regulation of Endothelial Delta-like 4 Expression Correlates with Vessel Maturation in Bladder CancerClinical Cancer Research, 2006
- Lessons from phase III clinical trials on anti-VEGF therapy for cancerNature Clinical Practice Oncology, 2006
- Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutantsGenes & Development, 2004
- Tie2 Expression and Phosphorylation in Angiogenic and Quiescent Adult TissuesCirculation Research, 1997